Konko raises $6M to automate patient journeys across Latin America
What's the deal? KonkoDealroom has a profile for this one. Try Dealroom →, a healthcare AI platform, raised $6 million in an early-stage round led by Hi VenturesDealroom has a profile for this one. Try Dealroom →. LifeX VenturesDealroom has a profile for this one. Try Dealroom →, SquareOne CapitalDealroom has a profile for this one. Try Dealroom →, GroundUp Ventures, and Phoenix Fund also joined, alongside angels from Harvard, MIT, GoogleDealroom has a profile for this one. Try Dealroom →, and Tesla.
What's the endgame? The New York and San José, Costa Rica-based company manages patient journeys — scheduling, triage, follow-ups, and record-keeping — for clinics and hospitals. It plans to spend the money on product development and expansion across Latin America.
The traction: In one year, Konko has managed more than 2 million patient interactions across 90 healthcare institutions and 60 specialties in Mexico, Colombia, and Costa Rica. It says AI handles 75% of those end-to-end.
Why now? Co-founder and chief executive officer Jean-Marc Goguikian built the platform after watching his wife, Dr. Juliana Vallejo, lose patient time to paperwork. He teamed up with Harvard classmate Michael Haddad, and the first deployment was at the clinic Goguikian founded with his wife.
"Applying AI to healthcare is more complex than most companies realize," Goguikian said. "Every clinic has unique workflows across dozens of systems, that's why we've spent years working with providers to build AI that understands how healthcare operates."
How it works: The platform started with appointment scheduling and grew into four products: Front Office handles messages, triage, and scheduling in any language; Reactivate recovers no-shows and closes referral loops; Unify consolidates each patient's context into a continuous record; and Analyze delivers real-time analytics. Konko says clients see up to 30% revenue growth and 50% higher productivity.
The signal: At $6 million, Konko's round sits in the middle of the pack for early-stage deals — a modest sum aimed at a large target. The company frames its market as the 5.6 billion people in the Global South, betting that interoperable, medical-grade AI can scale where clinics are overwhelmed and tooling is thin.
Image credit: Konko
